^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Nectin-4-targeted antibody-drug conjugate

    Related drugs:
    4d
    An open-label, single-center, randomized controlled phase II clinical study evaluating the safety and efficacy of neoadjuvant therapy with radiotherapy plus toripalimab versus 9MW2821 plus toripalimab in patients with upper tract urothelial carcinoma (UTUC) (ChiCTR2600117688)
    P2, N=60, Not yet recruiting, Peking University Third Hospital; Peking University Third Hospital
    New P2 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    Loqtorzi (toripalimab-tpzi) • bulumtatug fuvedotin (9MW2821)
    5d
    ENCORE: Enfortumab Vedotin as Monotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov)
    P2, N=34, Active, not recruiting, University of Utah | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Padcev (enfortumab vedotin-ejfv)
    5d
    SYS6002 vs PADCEV in Patients With Advanced Urothelial Carcinoma (clinicaltrials.gov)
    P2, N=100, Not yet recruiting, CSPC Megalith Biopharmaceutical Co.,Ltd.
    New P2 trial
    |
    Padcev (enfortumab vedotin-ejfv)
    9d
    Preferred Treatment Sequencing for Metastatic Urothelial Carcinoma (mUC) in the Era of Perioperative and First-Line (1L) Checkpoint Inhibitor: Results From a National Survey of Genitourinary Oncologists. (PubMed, Clin Genitourin Cancer)
    Survey-based opinions can effectively capture treatment selection preferences for mUC and could inform future clinical trial design. Additional data, including the impact of residual toxicity from 1L EVP, are needed to better understand real-world treatment sequencing patterns.
    Journal • Checkpoint inhibition
    |
    FGFR3 (Fibroblast growth factor receptor 3)
    |
    Keytruda (pembrolizumab) • Balversa (erdafitinib) • Padcev (enfortumab vedotin-ejfv)
    11d
    Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer (clinicaltrials.gov)
    P1, N=32, Recruiting, Emory University | Trial primary completion date: Dec 2025 --> Nov 2026
    Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1)
    |
    Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • Padcev (enfortumab vedotin-ejfv)
    14d
    Enfortumab Vedotin With or Without Pembrolizumab in Rare Genitourinary Tumors (E-VIRTUE) (clinicaltrials.gov)
    P2, N=68, Recruiting, National Cancer Institute (NCI) | Not yet recruiting --> Recruiting
    Enrollment open
    |
    CD4 (CD4 Molecule)
    |
    Keytruda (pembrolizumab) • Padcev (enfortumab vedotin-ejfv)
    14d
    New insights into Nectin-4 expression in testicular choriocarcinoma and its potential treatment with Enfortumab Vedotin: analysis of a multi-institutional series and association with clinical-pathological features. (PubMed, Virchows Arch)
    These findings confirm that testicular CHC expresses Nectin-4 and may be potentially targetable with EV. Future studies are needed to verify whether metastasis and chemotherapy up-regulate Nectin-4 and increase the sensitivity to EV, and whether the absence of Nectin-4 expression by cytotrophoblasts (the proliferative population of CHC) influences its potential efficacy.
    Journal
    |
    NECTIN4 (Nectin Cell Adhesion Molecule 4)
    |
    Padcev (enfortumab vedotin-ejfv)
    14d
    EV-4-EC: Study of EV for Recurrent Endometrial Carcinoma (clinicaltrials.gov)
    P2, N=12, Not yet recruiting, William Bradley | Initiation date: Nov 2025 --> Apr 2026
    Trial initiation date
    |
    NECTIN4 (Nectin Cell Adhesion Molecule 4)
    |
    Padcev (enfortumab vedotin-ejfv)
    15d
    A zirconium-89-labeled antibody-drug conjugate PET probe for noninvasive monitoring of Nectin4 expression in breast cancer and lung cancer. (PubMed, Cell Rep Phys Sci)
    Minimal tumor uptake is observed in blocking and Nectin4-negative controls, confirming specificity. Complementary fluorescence imaging further reveals the in vivo distribution of Padcev, providing valuable insights into optimal therapeutic time windows.
    Journal
    |
    NECTIN4 (Nectin Cell Adhesion Molecule 4)
    |
    Padcev (enfortumab vedotin-ejfv)
    18d
    ENVELOPE: Enfortumab Vedotin in Patients With Advanced Small Bowel Adenocarcinoma Refractory or Intolerant to Platinum-based Combination Therapy (clinicaltrials.gov)
    P2, N=27, Recruiting, National Cancer Center, Japan
    New P2 trial • Tumor mutational burden
    |
    BRAF (B-raf proto-oncogene)
    |
    Padcev (enfortumab vedotin-ejfv)
    18d
    A Study of Enfortumab Vedotin in People With Urothelial Carcinoma of the Upper Urinary Tract (clinicaltrials.gov)
    P2, N=24, Recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Jun 2026 --> Jun 2027 | Trial primary completion date: Jun 2026 --> Jun 2027
    Trial completion date • Trial primary completion date
    |
    CD4 (CD4 Molecule)
    |
    Padcev (enfortumab vedotin-ejfv)
    25d
    A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301) (clinicaltrials.gov)
    P3, N=608, Completed, Astellas Pharma Global Development, Inc. | Active, not recruiting --> Completed
    Trial completion
    |
    paclitaxel • docetaxel • Padcev (enfortumab vedotin-ejfv) • Javlor (vinflunine)